PDCD1 and cancer: Recent preclinical data have shown that the combination of OV and PD-1/PD-L1 inhibitors could work synergistically to exert cytotoxicity to cancer cells, eliminate immunosuppressive cells and elicit more potent and sustained systemic antitumor immunity.